|
Age (Mean ± StDev)
|
57.2 ± 8.6
|
60.7 ± 7.2
|
55.03 ± 8.9
|
< 0.0001
|
|
>65 years old (%)
|
40 (20.9%)
|
24 (28.6%)
|
16 (15.0%)
|
0.022
|
|
Sex (% Male)
|
164 (85.9%)
|
75 (89.3 %)
|
89 (83.2 %)
|
0.23
|
|
Body mass index > 30
|
78 (40.8%)
|
40 (47.6%)
|
42 (39.3%)
|
0.017
|
|
Etiologic Risk Factors *
| | | | |
|
Alcohol abuse
|
47 (24.6%)
|
18 (21.4%)
|
29 (27.1%)
|
0.37
|
|
Hepatitis C
|
104 (54.5%)
|
37 (44%)
|
67 (62.6%)
|
0.011
|
|
Hepatitis B
|
12 (6.2%)
|
5 (5.9%)
|
7 (6.5%)
|
0.86
|
|
Non-alcoholic steatohepatitis
|
14 (7.3%)
|
11 (13.1%)
|
3 (2.8%)
|
0.007
|
|
Cryptogenic
|
20 (10.5%)
|
13 (15.5%)
|
7 (6.5%)
|
0.057
|
|
Tumor Characteristics
| | | | |
|
Total tumor diameter (mean)+
|
5.42
|
5.81
|
5.125
|
0.29
|
|
Multinodular
|
107 (56%)
|
46 (54.8%)
|
61 (57%)
|
0.77
|
|
Macrovascular Invasion
|
27 (14.1%)
|
17 (20.2%)
|
10 (9.3%)
|
0.032
|
|
Microvascular Invasion Only
|
33(17.4%)
|
15 (17.9%)
|
18 (17.0%)
|
0.87
|
|
Portal Vein Thrombosis
|
33 (17.3%)
|
19 (22.6%)
|
14 (13.1%)
|
0.12
|
|
Laboratory Parameters++
| | | | |
|
MELD score (Mean ± SD)
|
15.91 ± 7.8
|
14.69 ± 7.19
|
16.86 ± 8.27
|
0.062
|
|
INR (Mean ± SD)
|
1.51 ± 0.52
|
1.37 ± 0.35
|
1.64 ± 0.59
|
0.001
|
|
Albumin (Mean ± SD)
|
3.3 ± 0.73
|
3.34 ± 0.82
|
3.27 ± 0.65
|
0.55
|
|
Bilirubin (Mean ± SD)
|
4.12 ± 5.69
|
3.34 ± 4.96
|
4.73 ± 6.16
|
0.071
|
|
Creatinine (Mean ± SD)
|
1.27 ± 0.81
|
1.36 ± 0.94
|
1.21 ± 0.70
|
0.20
|
|
Alpha fetoprotein IU/ml (median)
|
16.5+++
|
16.5
|
16.5
|
0.63
|
|
Alpha fetoprotein IU/ml (mean)
| |
978
|
542
|
0.35
|
|
HCC treatment
| | | | |
|
Chemoembolization
|
5(2.6%)
|
3(3.6%)
|
2 (1.9%)
|
0.76
|
|
Radiation
|
11(5.8%)
|
4 (4.8%)
|
7 (6.5%)
|
0.76
|
|
Ablation
|
7 (3.7%)
|
3 (3.6%)
|
4 (3.7%)
|
0.95
|
|
Transplant wait list time (mean number of months)
| |
5.9 months
|
7.5 months
|
0.43
|
